Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
- DOI
- 10.1093/cid/ciab750
- Published
- 2021-09-01
- Container
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/cid/ciab750,
title = {Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)},
author = {Jane R Schwebke and Ryan Sobel and Janet K Gersten and Steven A Sussman and Samuel N Lederman and Mark A Jacobs and B Todd Chappell and David L Weinstein and Alfred H Moffett and Nkechi E Azie and David A Angulo and Itzel A Harriott and Katyna Borroto-Esoda and Mahmoud A Ghannoum and Paul Nyirjesy and Jack D Sobel},
year = {2021},
journal = {Clinical Infectious Diseases},
doi = {10.1093/cid/ciab750},
url = {https://doi.org/10.1093/cid/ciab750}
}RIS
TY - JOUR TI - Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303) AU - Jane R Schwebke AU - Ryan Sobel AU - Janet K Gersten AU - Steven A Sussman AU - Samuel N Lederman AU - Mark A Jacobs AU - B Todd Chappell AU - David L Weinstein AU - Alfred H Moffett AU - Nkechi E Azie AU - David A Angulo AU - Itzel A Harriott AU - Katyna Borroto-Esoda AU - Mahmoud A Ghannoum AU - Paul Nyirjesy AU - Jack D Sobel PY - 2021 JO - Clinical Infectious Diseases DO - 10.1093/cid/ciab750 UR - https://doi.org/10.1093/cid/ciab750 ER -
APA
Schwebke, J. R., Sobel, R., Gersten, J. K., Sussman, S. A., Lederman, S. N., Jacobs, M. A., Chappell, B. T., Weinstein, D. L., Moffett, A. H., Azie, N. E., Angulo, D. A., Harriott, I. A., Borroto-Esoda, K., Ghannoum, M. A., Nyirjesy, P., & Sobel, J. D. (2021). Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab750
Source records
- crossref · retrieved 2026-09-26T18:18:30.088Z